Drug Trial Radar · NCT02510261
The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Participants Who Have Already Been Treated With ALN-TTR02 (Patisiran)
Last checked: Nov 19, 2026Latest source record: Dec 6, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
211
Actual
Start
Jul 16, 2015
Primary completion
Nov 23, 2022
Study completion Nov 23, 2022
Sponsor
- Lead sponsor
- Alnylam PharmaceuticalsAlnylam Pharmaceuticals (ALNY)
- Sponsor type
- Industry
- First posted
- Jul 29, 2015
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety and efficacy of long-term dosing with ALN-TTR02 (patisiran) in participants with transthyretin (TTR) mediated amyloidosis (ATTR).
Conditions
- Amyloidosis
Interventions
PatisiranDrug
Patisiran was administered IV.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Adverse Events (AEs) Leading to Study DiscontinuationTime frame: First dose up to 28 days after last dose of study drug (approximately 5.6 years)
Locations
56 sites in 21 countries. Site status is shown where the registry gives one.
Clinical Trial Site
La Mesa, California
Clinical Trial Site
Aurora, Colorado
Clinical Trial Site
Jacksonville, Florida
Clinical Trial Site
Chicago, Illinois
Clinical Trial Site
Baltimore, Maryland
Clinical Trial Site
Boston, Massachusetts
Clinical Trial Site
Detroit, Michigan
Clinical Trial Site
Rochester, Minnesota
Clinical Trial Site
Joplin, Missouri
Clinical Trial Site
St Louis, Missouri
Clinical Trial Site
Cooperstown, New York
Clinical Trial Site
New York, New York
Clinical Trial Site
New York, New York
Clinical Trial Site
Columbus, Ohio
Clinical Trial Site
Buenos Aires, Argentina
Clinical Trial Site
Westmead, Australia
Clinical Trial Site
Rio de Janeiro, Brazil
Clinical Trial Site
São Paulo, Brazil
Clinical Trial Site
Sofia, Bulgaria
Clinical Trial Site
Vancouver, British Columbia, Canada
Clinical Trial Site
Nicosia, Cyprus
Clinical Trial Site
Créteil, France
Clinical Trial Site
Le Kremlin-Bicêtre, France
Clinical Trial Site
Lille, France
Clinical Trial Site
Marseille, France
Clinical Trial Site
Fort de France, Martinique, France
Clinical Trial Site
Saint-Pierre, Reunion Island, France
Clinical Trial Site
Cologne, Germany
Clinical Trial Site
Heidelberg, Germany
Clinical Trial Site
Münster, Germany
Clinical Trial Site
Pavia, Italy
Clinical Trial Site
Rome, Italy
Clinical Trial Site
Sicily, Italy
Clinical Trial Site
Ehime, Japan
Clinical Trial Site
Fukuoka, Japan
Clinical Trial Site
Hiroshima, Japan
Clinical Trial Site
Kumamoto, Japan
Clinical Trial Site
Nagano, Japan
Clinical Trial Site
Ōita, Japan
Clinical Trial Site
Okawasuji, Japan
Showing 40 of 56 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.